These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22350899)

  • 21. Proteasome inhibitors as therapeutics.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Proteasome inhibitors].
    Saeki Y; Fukunaga K; Tanaka K
    Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 27. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2004 Jan; 145(2):67-74. PubMed ID: 14978877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
    Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
    Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
    [No Abstract]   [Full Text] [Related]  

  • 34. Proteasome inhibitors: poisons and remedies.
    Meiners S; Ludwig A; Stangl V; Stangl K
    Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Classification and synthesis of ubiquitin-proteasome inhibitor].
    Li J; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 37. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
    Cusack JC; Liu R; Xia L; Chao TH; Pien C; Niu W; Palombella VJ; Neuteboom ST; Palladino MA
    Clin Cancer Res; 2006 Nov; 12(22):6758-64. PubMed ID: 17121896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 20S proteasome and its inhibitors: crystallographic knowledge for drug development.
    Borissenko L; Groll M
    Chem Rev; 2007 Mar; 107(3):687-717. PubMed ID: 17316053
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.